Summary and conclusions: Glutathione and early (premature) inflammaging Chronic inflammatory diseases especially those compromising the lower respiratory system (chronic obstructive pulmonary disease, lower respiratory infections, cystic fibrosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome), diseases compromising the cardiovascular system (atherosclerosis, ischemic heart disease, stroke, and others), many other systemic inflammatory diseases like diabetes (274, 275)
The four large CDMOs (Bachem, AmbioPharm, CordenPharma, and PolyPeptide Group) are included for completeness
Naturally occurring peptides can't be easily patented, so they rarely attract a commercial sponsor
Finally, while sulforaphane is generally well-tolerated at low dose, clinical trials as higher sulforaphane doses can have unwanted side effects, such as lethargy, hypothermia, and gastrointestinal distress, although these generally occur at very high doses (Yagishita et al., 2019)